Imunon Secures $10M Financing to Advance Phase 3 OVATION 3 Trial Enrollment
IMNN•Imunon obtained a $10 million financing package to advance enrollment in its Phase 3 OVATION 3 trial. Financing mixes 250 preferred shares raising $2.5 million and debt notes $7.72 million, supporting the study following Phase 2 results showing median overall survival increased to 14.7 months (24.2 months with PARP inhibitors).
1. Financing Package and Objectives
Imunon announced a $10 million financing package intended to fund patient enrollment and execution of its Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patients. The capital infusion aims to reinforce the company’s cash position as it progresses toward pivotal trial milestones.
2. Financing Structure Details
The funding comprises the issuance of 250 non-redeemable, non-convertible preferred shares generating gross proceeds of $2.5 million and two secured promissory notes totaling $7.72 million. The notes carry annual interest rates of 8% and 5% and mature 18 months after issuance, with no attached warrants.
3. Phase 2 Clinical Data
Updated Phase 2 data for IMNN-001 showed median overall survival of 14.7 months versus 11.1 months with standard chemotherapy, rising to 24.2 months when combined with PARP inhibitors. These results have bolstered the scientific rationale for advancing the OVATION 3 pivotal study.
4. Strategic Impact and Milestones
Imunon structured the financing to limit shareholder dilution by avoiding deep discounts and warrant issuance, preserving existing equity value. Management expects the strengthened balance sheet to support trial enrollment completion and future regulatory discussions.
